Treatment as Prevention¨

Groundbreaking HIV vaccine enters late-stage testing in US and Europe

A potential vaccine is being welcomed by HIV prevention advocates with ‘cautious optimism’ A vaccine targeting multiple strains of HIV is going into late-stage testing in the US and Europe later this year, but HIV experts have expressed ‘optimistic caution.’ Pharmaceutical giant Johnson & Johnson (J&J) is gearing up to test a new type of

Groundbreaking HIV vaccine enters late-stage testing in US and Europe Read More »

International concern grows over Canada’s funding of fight against AIDS, tuberculosis and malaria

International concern is growing in medical and development circles that the Trudeau government is about to step back from its much-publicized global leadership on eradicating AIDS, tuberculosis and malaria. In 2016, Trudeau announced with fanfare that Canada was contributing $804-million to the Global Fund, a 24-per-cent increase to the international organization that aims to curb

International concern grows over Canada’s funding of fight against AIDS, tuberculosis and malaria Read More »

Global concerns rise over possibility Canada backs out of AIDS fight funding

International concern is growing in medical and development circles that the Trudeau government is about to step back from its much-publicized global leadership on eradicating AIDS, tuberculosis and malaria. In 2016, Trudeau announced with fanfare that Canada was contributing $804 million to the Global Fund, a 24-per-cent increase to the international organization that aims to

Global concerns rise over possibility Canada backs out of AIDS fight funding Read More »

Comparative Outcomes And Service Utilization Trends (COAST) Fact Sheet

The Comparative Outcomes And Service Utilization Trends (COAST) study is a population-based cohort study that aims to examine the health outcomes and health service use of people living with HIV (PLHIV), including both those who are accessing and not accessing antiretroviral therapy, as compared to the general population of British Columbia. The study comprises two

Comparative Outcomes And Service Utilization Trends (COAST) Fact Sheet Read More »

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below